A MedTech pitch deck lives or dies on a single slide that most founders treat as an afterthought: the regulatory slide. Specialist MedTech investors in 2026 will read it first, before product, before market, before traction, because it tells them in thirty seconds whether the team understands what they are building. A good regulatory slide states the device class and the specific classification rule under Annex VIII of Regulation (EU) 2017/745, the conformity assessment route, the Notified Body status, an honest CE mark timeline with buffer, the regulatory budget loaded into cost of goods sold, and the PRRC coverage under Article 15. A bad regulatory slide hides all of that behind the phrase "we will be CE marked by Q4" and the round dies in the first diligence pass without anyone telling the founder why.

By Felix Lenhard and Tibor Zechmeister. Last updated 10 April 2026.

TL;DR

  • The regulatory slide is the single highest-leverage page in a MedTech pitch deck. Specialist investors read it first.
  • A credible slide names the device class, the specific classification rule, the conformity assessment route, the Notified Body engagement status, an honest timeline with delay buffer, the regulatory budget as part of cost of goods sold, and the Person Responsible for Regulatory Compliance (PRRC) plan under MDR Article 15.
  • Uncertainty is not a weakness. Hidden uncertainty is. A founder who names the open question and the plan to close it wins credibility. A founder who hedges everything loses it.
  • The red flags that kill rounds are the same ones every time: vague intended purpose, undefended classification, "we do not need a Notified Body" when they do, a timeline with no buffer, and a budget that treats MDR compliance as a post-launch problem.
  • The slide is not a regulatory document. It is a trust signal. Its job is to prove that the founder will not burn the investor's money on compliance theatre.

Why the regulatory slide matters more than the traction slide

In a generalist tech pitch, the traction slide is where the round is won. Investors look at the growth curve, they run the cohort math in their head, and if the numbers work they lean in. In a MedTech pitch, the traction slide is often a promise, not a fact. The device is not on the market yet. There is no MRR. There is no user count that maps to revenue. What the specialist MedTech investor is actually buying is the probability that the team will get a regulated product through a Notified Body audit and into reimbursement.

That probability lives on the regulatory slide.

A seasoned MedTech investor reading a deck will flip to the regulatory slide first. Not because they do not care about the product. They do. But because the regulatory slide is where unqualified founders are exposed fastest. If the classification rationale is wrong, nothing else in the deck matters. If the team thinks their Class IIa software does not need a Notified Body, the conversation is over before it starts. The regulatory slide is the fastest filter in MedTech diligence, and founders who understand this prepare for it accordingly.

The flip side is the opportunity. A clean, confident, specific regulatory slide separates a founder from ninety percent of the pitches a specialist fund sees in a quarter. It is one of the few places in a MedTech pitch where preparation beats charisma, and where a first-time founder with the right facts outperforms a repeat founder who improvised the deck.

What to show on the slide

A regulatory slide is not an Annex II technical file summary. It is a one-page trust signal. The discipline is to compress the entire regulatory plan into facts an investor can hold in their head for the rest of the meeting. Seven items, no more.

1. Device class and the classification rule. State the class. I, IIa, IIb, or III. And name the specific rule from Annex VIII of Regulation (EU) 2017/745 that drives it. If the device is software, say whether you are classifying under Rule 11 and explain why. If there is borderline ambiguity, state the ambiguity honestly and name the class you are defending. Investors do not want false certainty; they want a defensible position.

2. Conformity assessment route. Name the Annex route under MDR you are using. Class I self-declared is a different slide than Class IIa under Annex IX. Say which one applies. If a Notified Body is required. Which it is for anything above Class I and for certain Class I subcategories. The slide should make that explicit.

3. Notified Body status. Name the Notified Body you are engaging with, the stage of the conversation (initial contact, pre-submission, contract signed, audit booked), and a realistic view of their current capacity window. Investors know there is a capacity bottleneck in the European Notified Body system. Acknowledging it on the slide is a trust signal. Ignoring it is a red flag.

4. Timeline with buffer. A CE mark timeline that does not include a buffer for Notified Body delay, clinical evaluation iteration, or technical file deficiency letters is a fantasy. Show the honest date and mark the buffer explicitly. The sophisticated investor will subtract the buffer mentally either way. Better that you show it than that they guess at it.

5. Budget as cost of goods sold. The regulatory budget line should show up as part of COGS, not as an optional add-on. This signals that the founder has absorbed the core economic reality of MedTech: compliance cost is structural, not negotiable. Break out the Notified Body fees, the clinical evidence cost, the QMS build cost under EN ISO 13485:2016+A11:2021, and the technical file production cost.

6. PRRC coverage. Under MDR Article 15, a Person Responsible for Regulatory Compliance must be permanently and continuously available to the manufacturer. Micro and small enterprises are allowed to have the PRRC available on a contracted basis rather than in-house. State who the PRRC is or will be, whether they are in-house or contracted, and how this changes with the round. An investor who has funded MedTech before will check this.

7. One-line clinical evaluation strategy. Name the approach under MDR Article 61. Literature review, equivalence route, or your own clinical investigation. And whether you plan to rely on the equivalence pathway. Do not hide this. It drives the biggest cost line in most MedTech startups.

Seven facts. One slide. Ninety seconds of speaking time. That is the target.

How to frame uncertainty without losing the room

Every MedTech startup has open regulatory questions. The classification edge case that is not fully resolved. The Notified Body that has not yet confirmed scope. The clinical dataset that still has gaps. A founder who tries to hide these will be caught in diligence and will lose the round. A founder who names them, calls out the plan to close them, and frames them as known-unknowns will actually gain credibility.

The language discipline is specific. Say: "Our current view is Class IIa under Rule 11, driven by the following reasoning. There is a borderline case around the driver function that we are working through with our regulatory advisor, and we expect to have a confirmed position within eight weeks." That is a clean uncertainty statement. It tells the investor what you know, what you do not know, and when you will know more.

Compare that with: "We expect to be Class IIa, we are still working through some details, our advisor is handling it." That is the same underlying situation dressed in vague language, and it fails. The investor cannot tell whether you have thought about it or are hoping it goes away.

The rule is that specific uncertainty beats vague confidence every time in MedTech diligence. Specialist investors have seen enough companies hit the wall that they are trained to distinguish the two. Hide nothing; just frame the open questions with precision.

The red flags that kill rounds

There are patterns that make specialist MedTech investors close the deck and move on. None of them are fatal in themselves, but combined they signal a founder who has not done the work.

The vague intended purpose. Intended purpose is the anchor of everything under MDR. A founder who cannot state it in one sentence that would survive on a label does not understand their own regulatory strategy. We have watched founders pitch a slide with aspirational claims. "AI-powered clinical decision platform for personalised medicine". That have no operable meaning under MDR. The first serious question from the investor ("what does your intended purpose say on the label?") ends the meeting.

"We do not need a Notified Body." Sometimes this is true. Class I self-declared devices do not need a Notified Body for the conformity assessment itself. But the statement is wrong often enough that it is a red flag every time it appears unsupported. If the founder cannot immediately explain the specific class and Annex route that justifies it, the statement reads as wishful thinking.

The two-month timeline. A founder who puts CE mark two months out without a Notified Body audit already booked is either misinformed or hoping the investor will not check. Tibor has seen this pattern repeatedly: a team announcing CE mark in Q2, still in initial Notified Body conversations in Q1, and surprised when the date slips by twelve months. Felix has coached founders through the same collision. An investor who has seen this pattern once will never fund it again.

The hidden regulatory budget. If the regulatory cost is buried in a footnote or not shown at all, the investor assumes the founder has not priced it. The round either dies or the term sheet comes back with aggressive milestone tranching that will punish the company later.

The missing PRRC plan. A deck with no mention of PRRC coverage tells the investor the founder has not read Article 15. It is a small item on the slide and a large signal about the depth of preparation.

The reimbursement silence. Reimbursement is not a regulatory requirement under MDR, but specialist MedTech investors now treat it as table stakes for a fundable pitch. A deck that says nothing about reimbursement is telling the investor that the team considers it a post-launch problem. That ends the meeting for most specialist funds in 2026.

What good and bad slides look like in practice

A bad slide, in effect:

Regulatory - CE mark Q4 2026 - Class IIa - Working with Notified Body - QMS in progress

Every line on this slide is defensible in isolation and yet the whole page tells the investor nothing. Which Notified Body? At what stage? Why Class IIa. Under which rule? What does "in progress" mean for the QMS? There is no budget, no PRRC, no clinical plan, no buffer. An investor reading this slide will assume the founder does not know the answers.

A good slide, in effect:

Regulatory strategy - Device class: IIa under MDR Annex VIII, Rule 11 (software driving diagnosis but not directly driving therapy). - Route: Annex IX conformity assessment with Notified Body. - Notified Body: [Named NB], scoping contract signed Feb 2026, pre-submission meeting June 2026, audit window Q1 2027. - Timeline: CE mark target Q3 2027. Buffer of six months included to absorb deficiency-letter iteration. - Clinical evaluation (MDR Art. 61): Literature review plus targeted prospective evidence from two EU sites; equivalence not claimed. - PRRC (MDR Art. 15): Contracted senior RA professional in place under the small-enterprise provision; in-house hire planned post-Series A. - Budget: Regulatory cost line EUR X loaded into COGS, broken down by NB fees, clinical evidence, QMS, technical file.

Same company. Different preparation. The second slide tells the specialist investor that the team has read the regulation, has engaged with a Notified Body, has priced the work, and has thought about what the next round buys. It takes the meeting forward to the clinical and commercial questions, which is exactly what the founder wants.

How to answer the investor questions that follow the slide

After the slide comes the questioning. Specialist MedTech investors have a standard pattern and founders who rehearse for it walk out with term sheets.

"Why this class and not the one up?" The investor is checking whether you have defended the classification against the obvious harder case. The honest answer names the rule, the specific language that supports your position, and. If there is a harder case. The rationale for why you are not in it. If the honest answer is "we are not sure yet," say so and name the date by which you will be.

"Who else have you spoken to at Notified Body level?" The investor is checking capacity risk. Ideally you have had real conversations with more than one Notified Body and have chosen the one whose capacity and scope match your device. If you have only spoken to one, say so, and name the fallback.

"What is your worst-case timeline?" The investor is probing your buffer logic. The answer is a specific date under specific assumptions. Not "we think we can still make it if things go well."

"What happens if your clinical evaluation comes back deficient?" The investor wants to see that you have modelled the deficiency-letter iteration cycle and priced it into the runway. Founders who have not thought about this stumble here.

"How does the regulatory cost change at the next round?" The investor is checking whether you understand that post-market surveillance under MDR Article 83 and ongoing QMS maintenance are permanent cost lines, not one-time projects.

"Who owns regulatory on your team?" The investor wants to see a specific person. Internal or contracted. With explicit ownership. "Everyone" is the wrong answer. "Nobody yet, but hiring is in the plan" is an acceptable answer if the plan is specific.

A founder who has rehearsed these six questions and can answer each in under a minute with named facts will close rounds that a smarter founder without rehearsal will lose.

The Subtract to Ship angle. The slide is the audit

The Subtract to Ship framework says that every activity, every document, and every line of the deck must trace back to a purpose. The regulatory slide is the cleanest example of the discipline in the whole pitch. Everything on it has to earn its place. The class traces to Annex VIII. The route traces to the class. The Notified Body traces to the route. The timeline traces to the Notified Body's capacity. The budget traces to the timeline. The PRRC traces to Article 15. Nothing on the slide is decoration. Every line is load-bearing.

This is the same discipline that applies to the technical file itself. Subtract everything that does not directly satisfy a specific MDR obligation. What remains is the work that actually gets you certified. And the slide that actually gets you funded. The two disciplines are the same discipline. A founder who has internalised it for the regulatory slide will apply it to the technical file, to the QMS, and to every hire decision downstream, which is exactly what the specialist investor is trying to detect when they read the slide in the first place.

Reality Check. Where do you stand?

  1. Can you state your intended purpose in one sentence that would survive on a CE label without a marketing rewrite?
  2. Can you name the specific MDR classification rule that drives your class, and defend it against the next-harder-case classification?
  3. Have you had a real conversation with at least one Notified Body, and do you know where you stand in their queue?
  4. Does your CE mark timeline include an explicit buffer for deficiency-letter iteration, and is the buffer visible on the slide?
  5. Is your regulatory cost loaded into cost of goods sold on your financial model, not treated as a one-time project?
  6. Do you have a named PRRC. In-house or contracted. And can you explain the Article 15 small-enterprise provision if the investor asks?
  7. Is your clinical evaluation approach under MDR Article 61 a concrete plan, not a sentence that contains the word "equivalence" and nothing else?
  8. Can you deliver the regulatory slide in ninety seconds, cold, without hedging and without filler?

Frequently Asked Questions

Where in the pitch deck should the regulatory slide sit? Near the front, immediately after the problem and product slides and before the market and traction slides. Specialist MedTech investors will read it first regardless of its position, so putting it near the front signals that the team understands its importance. Burying it at slide 18 is itself a red flag.

How detailed should the regulatory slide actually be? One slide, seven facts, ninety seconds of speaking time. Any more and the slide becomes a document; any less and it becomes a vague promise. The detail lives in the data room and the appendix; the slide itself is a trust signal, not a technical file summary.

Should I mention Notified Body capacity constraints on the slide? Yes. Specialist investors already know about the bottleneck in the European Notified Body system. Naming it on the slide. And showing that your timeline absorbs it. Is a credibility move. Ignoring it signals that you have not done the homework.

Do I need to name my Notified Body on the slide? If the relationship is real, yes. Naming the Notified Body and the stage of the engagement is one of the strongest trust signals on the whole deck. If you have not yet engaged one, say so honestly and name the ones you are evaluating.

What if my classification is genuinely uncertain? Say so, name the defensible position, and state the date by which you will have it resolved. Specific uncertainty is a strength in diligence. Vague confidence is a weakness. Investors distinguish the two reliably.

Is the regulatory slide the same for Class I and Class III devices? The structure is the same; the content is different. A Class I self-declared device needs to justify the class and show the technical file plan, but does not need a Notified Body line. A Class III device needs a much heavier clinical evaluation line and a longer timeline. The seven items stay; the weight shifts.

What about FDA? Should the slide mention the US pathway? Only if it is a real part of your plan for the round you are raising. If you are raising a European round to reach CE mark, mention FDA briefly as a future line and keep the slide focused on MDR. Mixing the two pathways on one slide usually weakens both.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Article 10 (manufacturer obligations), Article 15 (Person Responsible for Regulatory Compliance), Article 51 and Annex VIII (classification rules), Article 61 (clinical evaluation), Article 83 (post-market surveillance system). Official Journal L 117, 5.5.2017.
  2. EN ISO 13485:2016 + A11:2021. Medical devices. Quality management systems. Requirements for regulatory purposes.
  3. Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards transitional provisions for certain medical devices and in vitro diagnostic medical devices.

This post is part of the Funding, Business Models & Reimbursement series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. When the regulatory slide turns into the diligence question you cannot answer in the room. The classification edge case, the Notified Body scope question, the PRRC small-enterprise clause. A sparring partner who has sat on both sides of a MedTech term sheet is the shortest path to a round you will still be proud of once the money has cleared.